{"id":435470,"date":"2021-02-15T01:19:01","date_gmt":"2021-02-15T06:19:01","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=435470"},"modified":"2021-02-15T01:19:01","modified_gmt":"2021-02-15T06:19:01","slug":"targovax-receives-fast-track-designation-for-oncos-102","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/","title":{"rendered":"Targovax receives Fast-Track designation for ONCOS-102"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">&#8211; The US FDA grants ONCOS-102 Fast-Track designation for malignant pleural mesothelioma<\/h2>\n<h2 class=\"xn-hedline\">&#8211;  Fast-Track opens the potential for expedited development and review with the US FDA<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">OSLO, Norway<\/span>, <span class=\"xn-chron\">Feb. 15, 2021<\/span> \/PRNewswire\/ &#8212; <b>Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that its lead clinical candidate ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA. \u00a0<\/b><\/p>\n<p>The US FDA granted Fast-Track designation to ONCOS-102 based on encouraging pre-clinical and clinical efficacy associated with broad immune activation observed to date. Receiving this designation is an endorsement by the US FDA of the strength of the ONCOS-102 data package.<\/p>\n<p>The FDA Fast Track-designation is awarded to therapies with potential to address unmet medical needs in serious medical conditions and allows for more frequent interactions with the FDA to expedite clinical development, as well as the regulatory review processes. Fast-Track products have improved likelihood of receiving Priority Review for a future Biologics License Application (BLA) and may be allowed to submit parts of the application early to shorten review time.<\/p>\n<p>The Fast-Track approval comes in addition to ONCOS-102&#8217;s existing Orphan Drug Designation (ODD) with both the US FDA and European EMA in the mesothelioma indication, which provides ONCOS-102 market exclusivity for 7 and 10 years in the <span class=\"xn-location\">USA<\/span> and EU, respectively, from the date of BLA grant. <\/p>\n<p>\n        <b>Dr. <span class=\"xn-person\">Ingunn Munch Lindvig<\/span>, VP Regulatory Affairs, said:<\/b>\u00a0&#8220;Securing this Fast-Track designation is a very important milestone for the ONCOS-102 program. Most importantly Fast-Track validates the strong potential of ONCOS-102 as a future treatment option for solid tumors with high unmet medical need&#8221;. <\/p>\n<p>\n        <b>For further information, please contact:<\/b><br \/>\n        <br \/>\n        <span class=\"xn-person\">Renate Birkeli<\/span>, Investor Relations<br \/>Phone: +47 922 61 624<br \/>Email: <a target=\"_blank\" href=\"mailto:renate.birkeli@targovax.com\" rel=\"nofollow noopener noreferrer\">renate.birkeli@targovax.com <\/a><\/p>\n<p><b>Media enquires:<\/b><br \/><span class=\"xn-person\">Andreas Tinglum<\/span> &#8211; Corporate Communications (<span class=\"xn-location\">Norway<\/span>)<br \/>Phone: +47 9300 1773<br \/>Email: <a target=\"_blank\" href=\"mailto:andreas.tinglum@corpcom.no\" rel=\"nofollow noopener noreferrer\">andreas.tinglum@corpcom.no <\/a><\/p>\n<p>\n        <b>IR enquires:<\/b><br \/>\n        <br \/>\n        <span class=\"xn-person\">Kim Sutton Golodetz<\/span> &#8211; LHA Investor Relations (US)<br \/>Email: <a target=\"_blank\" href=\"mailto:kgolodetz@lhai.com\" rel=\"nofollow noopener noreferrer\">kgolodetz@lhai.com<\/a><br \/>Phone: +1 212-838-3777<br \/>\u00a0<\/p>\n<p>This information was brought to you by Cision <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3067576-1&amp;h=1182757640&amp;u=http%3A%2F%2Fnews.cision.com%2F&amp;a=http%3A%2F%2Fnews.cision.com\" rel=\"nofollow noopener noreferrer\">http:\/\/news.cision.com<\/a><\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3067576-1&amp;h=1888124343&amp;u=https%3A%2F%2Fnews.cision.com%2Ftargovax%2Fr%2Ftargovax-receives-fast-track-designation-for-oncos-102%2Cc3286718&amp;a=https%3A%2F%2Fnews.cision.com%2Ftargovax%2Fr%2Ftargovax-receives-fast-track-designation-for-oncos-102%2Cc3286718\" rel=\"nofollow noopener noreferrer\">https:\/\/news.cision.com\/targovax\/r\/targovax-receives-fast-track-designation-for-oncos-102,c3286718<\/a>\n      <\/p>\n<p>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO79636&amp;sd=2021-02-15\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/targovax-receives-fast-track-designation-for-oncos-102-301228114.html\">http:\/\/www.prnewswire.com\/news-releases\/targovax-receives-fast-track-designation-for-oncos-102-301228114.html<\/a><\/p>\n<p>SOURCE  Targovax<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO79636&amp;Transmission_Id=202102150115PR_NEWS_USPR_____IO79636&amp;DateId=20210215\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; The US FDA grants ONCOS-102 Fast-Track designation for malignant pleural mesothelioma &#8211; Fast-Track opens the potential for expedited development and review with the US FDA PR Newswire OSLO, Norway, Feb. 15, 2021 \/PRNewswire\/ &#8212; Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that its lead clinical candidate ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA. \u00a0 The US FDA granted Fast-Track designation to ONCOS-102 based on encouraging pre-clinical and clinical efficacy associated with broad immune activation observed to date. Receiving this designation is an endorsement by the US FDA of the strength of the ONCOS-102 data package. The FDA Fast Track-designation is awarded &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Targovax receives Fast-Track designation for ONCOS-102&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-435470","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Targovax receives Fast-Track designation for ONCOS-102 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Targovax receives Fast-Track designation for ONCOS-102 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; The US FDA grants ONCOS-102 Fast-Track designation for malignant pleural mesothelioma &#8211; Fast-Track opens the potential for expedited development and review with the US FDA PR Newswire OSLO, Norway, Feb. 15, 2021 \/PRNewswire\/ &#8212; Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that its lead clinical candidate ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA. \u00a0 The US FDA granted Fast-Track designation to ONCOS-102 based on encouraging pre-clinical and clinical efficacy associated with broad immune activation observed to date. Receiving this designation is an endorsement by the US FDA of the strength of the ONCOS-102 data package. The FDA Fast Track-designation is awarded &hellip; Continue reading &quot;Targovax receives Fast-Track designation for ONCOS-102&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-15T06:19:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO79636&amp;sd=2021-02-15\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-receives-fast-track-designation-for-oncos-102\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-receives-fast-track-designation-for-oncos-102\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Targovax receives Fast-Track designation for ONCOS-102\",\"datePublished\":\"2021-02-15T06:19:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-receives-fast-track-designation-for-oncos-102\\\/\"},\"wordCount\":354,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-receives-fast-track-designation-for-oncos-102\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO79636&amp;sd=2021-02-15\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-receives-fast-track-designation-for-oncos-102\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-receives-fast-track-designation-for-oncos-102\\\/\",\"name\":\"Targovax receives Fast-Track designation for ONCOS-102 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-receives-fast-track-designation-for-oncos-102\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-receives-fast-track-designation-for-oncos-102\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO79636&amp;sd=2021-02-15\",\"datePublished\":\"2021-02-15T06:19:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-receives-fast-track-designation-for-oncos-102\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-receives-fast-track-designation-for-oncos-102\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-receives-fast-track-designation-for-oncos-102\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO79636&amp;sd=2021-02-15\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=IO79636&amp;sd=2021-02-15\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/targovax-receives-fast-track-designation-for-oncos-102\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Targovax receives Fast-Track designation for ONCOS-102\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Targovax receives Fast-Track designation for ONCOS-102 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/","og_locale":"en_US","og_type":"article","og_title":"Targovax receives Fast-Track designation for ONCOS-102 - Market Newsdesk","og_description":"&#8211; The US FDA grants ONCOS-102 Fast-Track designation for malignant pleural mesothelioma &#8211; Fast-Track opens the potential for expedited development and review with the US FDA PR Newswire OSLO, Norway, Feb. 15, 2021 \/PRNewswire\/ &#8212; Targovax ASA (OSE: TRVX), a clinical stage immune-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that its lead clinical candidate ONCOS-102 has received Fast-Track designation in malignant pleural mesothelioma from the US FDA. \u00a0 The US FDA granted Fast-Track designation to ONCOS-102 based on encouraging pre-clinical and clinical efficacy associated with broad immune activation observed to date. Receiving this designation is an endorsement by the US FDA of the strength of the ONCOS-102 data package. The FDA Fast Track-designation is awarded &hellip; Continue reading \"Targovax receives Fast-Track designation for ONCOS-102\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-15T06:19:01+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO79636&amp;sd=2021-02-15","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Targovax receives Fast-Track designation for ONCOS-102","datePublished":"2021-02-15T06:19:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/"},"wordCount":354,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO79636&amp;sd=2021-02-15","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/","name":"Targovax receives Fast-Track designation for ONCOS-102 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO79636&amp;sd=2021-02-15","datePublished":"2021-02-15T06:19:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO79636&amp;sd=2021-02-15","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=IO79636&amp;sd=2021-02-15"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/targovax-receives-fast-track-designation-for-oncos-102\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Targovax receives Fast-Track designation for ONCOS-102"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/435470","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=435470"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/435470\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=435470"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=435470"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=435470"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}